Literature DB >> 15706001

Early antibiotic treatment for BAL-confirmed ventilator-associated pneumonia: a role for routine endotracheal aspirate cultures.

Fabrice Michel1, Bruno Franceschini, Pierre Berger, Jean-Michel Arnal, Marc Gainnier, Jean-Marie Sainty, Laurent Papazian.   

Abstract

STUDY
OBJECTIVES: To test whether routine quantitative cultures of endotracheal aspirates obtained before the onset of ventilator-associated pneumonia (VAP) could help to predict the causative microorganisms and to select early appropriate antimicrobial therapy before obtaining BAL culture results.
DESIGN: Prospective observational study.
SETTING: French medical ICU. PATIENTS: A total of 299 patients received mechanical ventilation for at least 48 h.
INTERVENTIONS: Endotracheal aspiration (EA) was performed twice weekly in all mechanically ventilated patients. A diagnosis of VAP was made by BAL culture. Only the EA performed just before the suspicion of VAP (EA-pre) were evaluated. This strategy (ie, the EA-pre-based strategy) was compared with an antibiotic therapy that would have been prescribed if the recommendations of both the American Thoracic Society (ATS) and Trouillet et al (Am J Respir Crit Care Med 1998; 157:531-539) had been applied. MEASUREMENTS AND
RESULTS: VAP was diagnosed (by BAL culture) in 41 of the 75 patients in whom BAL was performed. Among the 41 BAL specimens that were positive for VAP, EA-pre had identified the same microorganisms (with the same antibiotic resistance patterns) in 34 cases (83%). In one case, EA-pre was not available at the time BAL was performed (a case of early-onset VAP), but the empiric antibiotic therapy was adequate. While EA-pre did not give the same results as the BAL culture, the antibiotic therapy based on the results of the EA-pre was adequate in four other cases. Finally, antibiotic therapy was delayed in only two cases. Antibiotic treatment was therefore adequate in 38 of the 40 assessable cases (95%). If the Trouillet-based strategy had been used, the antibiotic treatment would have been adequate in 34 of the 41 cases (83%; p = 0.15 [vs EA-pre strategy]). Based on the ATS classification, the antibiotic treatment would have been adequately prescribed in only 28 of the 41 cases (68%; p = 0.005 [vs EA-pre strategy]).
CONCLUSIONS: Routine EA performed twice a week makes it possible to prescribe adequate antibiotic therapy (while waiting for BAL culture results) in 95% of the patients in whom a VAP is ultimately diagnosed by BAL culture.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15706001     DOI: 10.1378/chest.127.2.589

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  46 in total

1.  Non-invasive detection of pulmonary pathogens in ventilator-circuit filters by PCR.

Authors:  Richard J Isaacs; Ken Debelak; Patrick R Norris; Judith M Jenkins; Jeffrey C Rooks; Todd R Young; Addison K May; Erik M Boczko
Journal:  Am J Transl Res       Date:  2012-01-05       Impact factor: 4.060

2.  Outcome in bacteremia associated with nosocomial pneumonia and the impact of pathogen prediction by tracheal surveillance cultures.

Authors:  Pieter Depuydt; Dominique Benoit; Dirk Vogelaers; Geert Claeys; Gerda Verschraegen; Koenraad Vandewoude; Johan Decruyenaere; Stijn Blot
Journal:  Intensive Care Med       Date:  2006-09-16       Impact factor: 17.440

3.  Ventilator-associated pneumonia: diagnosis, treatment, and prevention.

Authors:  Steven M Koenig; Jonathon D Truwit
Journal:  Clin Microbiol Rev       Date:  2006-10       Impact factor: 26.132

4.  Maximizing rates of empiric appropriate antibiotic therapy with minimized use of broad-spectrum agents: are surveillance cultures the key?

Authors:  S Blot; P Depuydt; D Vogelaers
Journal:  Intensive Care Med       Date:  2008-08-19       Impact factor: 17.440

Review 5.  [Nosocomial pneumonia. Prevention and diagnostic].

Authors:  T Perl; M Quintel
Journal:  Anaesthesist       Date:  2011-03       Impact factor: 1.041

6.  The role of surveillance cultures in the prediction of susceptibility patterns of Gram-negative bacilli in the intensive care unit.

Authors:  H Baba; G R Nimmo; A M Allworth; R J Boots; Y Hayashi; J Lipman; D L Paterson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-01-11       Impact factor: 3.267

7.  A pilot study of the noninvasive assessment of the lung microbiota as a potential tool for the early diagnosis of ventilator-associated pneumonia.

Authors:  Addison K May; Jacob S Brady; Joann Romano-Keeler; Wonder P Drake; Patrick R Norris; Judith M Jenkins; Richard J Isaacs; Erik M Boczko
Journal:  Chest       Date:  2015-06       Impact factor: 9.410

8.  Correlation between sputum and bronchoalveolar lavage fluid cultures.

Authors:  Grégory Dubourg; Cédric Abat; Jean-Marc Rolain; Didier Raoult
Journal:  J Clin Microbiol       Date:  2014-12-24       Impact factor: 5.948

Review 9.  [Diagnosis and therapy of sepsis. Guidelines of the German Sepsis Society Inc. and the German Interdisciplinary Society for Intensive and Emergency Medicine].

Authors:  K Reinhart; F Brunkhorst; H Bone; H Gerlach; M Gründling; G Kreymann; P Kujath; G Marggraf; K Mayer; A Meier-Hellmann; C Peckelsen; C Putensen; M Quintel; M Ragaller; R Rossaint; F Stüber; N Weiler; T Welte; K Werdan
Journal:  Internist (Berl)       Date:  2006-04       Impact factor: 0.743

10.  Prevention, diagnosis, therapy and follow-up care of sepsis: 1st revision of S-2k guidelines of the German Sepsis Society (Deutsche Sepsis-Gesellschaft e.V. (DSG)) and the German Interdisciplinary Association of Intensive Care and Emergency Medicine (Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin (DIVI)).

Authors:  K Reinhart; F M Brunkhorst; H-G Bone; J Bardutzky; C-E Dempfle; H Forst; P Gastmeier; H Gerlach; M Gründling; S John; W Kern; G Kreymann; W Krüger; P Kujath; G Marggraf; J Martin; K Mayer; A Meier-Hellmann; M Oppert; C Putensen; M Quintel; M Ragaller; R Rossaint; H Seifert; C Spies; F Stüber; N Weiler; A Weimann; K Werdan; T Welte
Journal:  Ger Med Sci       Date:  2010-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.